Azitra Inc
Organization details
- Legal name
- Azitra Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Branford
- Headquarters state / province
- Connecticut
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AZTR
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0001701478
- EIN
- 46-4478536
Board of directors
-
Andrew McClary · DirectorSince 2023
-
Barbara Ryan · DirectorSince 2023
-
Francisco D. Salva · Director · President and CEOSince 2023
-
John R. Schroer · DirectorSince 2023
-
Travis Whitfill · Director · Chief Operating OfficerSince 2023
Chief executives
Director election results
Annual meeting of June 23, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.3%
-
82.2%
-
92.4%
-
92.7%
Board connections
2 of this board's directors also sit on 4 other boards. 4 are in the same sector.
-
IN8bio Inc. Same sectorvia Travis Whitfill
-
INVO Fertility Inc. Same sectorvia Barbara Ryan
-
Indivior Pharmaceuticals Inc. Same sectorvia Barbara Ryan
-
MiNK Therapeutics Inc. Same sectorvia Barbara Ryan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Francisco D. Salva Director, Officer (President and CEO) | Derivative conversion | +4,064,050 | — | — |
| Mar 29, 2024 | Staskey Norm Officer (Chief Financial Officer) | Open-market purchase | +47,600 | $0.21 | $9,996 |
| Feb 13, 2024 | Travis Whitfill Director, Officer (Chief Operating Officer) | Open-market purchase | +15,000 | $0.30 | $4,500 |
| Feb 13, 2024 | Staskey Norm Officer (Chief Financial Officer) | Open-market purchase | +3,300 | $0.30 | $990 |
| Feb 13, 2024 | Francisco D. Salva Director, Officer (President and CEO) | Open-market purchase | +333,300 | $0.30 | $99,990 |
| Jun 21, 2023 | Andrew McClary Director | Derivative conversion | +42,347 | — | — |
| Jun 21, 2023 | Cavu Advisors, LLC 10% owner | Open-market sale | −77,953 | — | — |
| Jun 21, 2023 | BIOS Fund III NT, LP 10% owner | Open-market sale | −77,953 | — | — |
| Jun 21, 2023 | Francisco D. Salva Director, Officer (President and CEO) | Grant or award | +5,000 | $5.00 | $25,000 |
| Jun 21, 2023 | Travis Whitfill Director, Officer (Chief Operating Officer) | Grant or award | +250 | $5.00 | $1,250 |
| Jun 21, 2023 | Bayer World Investments B.V. 10% owner | Derivative conversion | +1,307,401 | — | — |
| Jun 21, 2023 | Andrew McClary Director | Derivative conversion | +16,975 | — | — |
| Jun 21, 2023 | Cavu Advisors, LLC 10% owner | Open-market purchase | +197,701 | — | — |
| Jun 21, 2023 | BIOS Fund III NT, LP 10% owner | Open-market purchase | +197,701 | — | — |
| Jun 21, 2023 | Cavu Advisors, LLC 10% owner | Open-market purchase | +69,880 | $5.00 | $349,400 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Azitra Inc
Who is the CEO of Azitra Inc?
Francisco D. Salva has been Azitra Inc's President and CEO since June 2023.
How many directors are on Azitra Inc's board?
Azitra Inc's board has 5 directors: Andrew McClary, Barbara Ryan, Francisco D. Salva, John R. Schroer and Travis Whitfill.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="azitra-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.